There is growing evidence that psychedelic drugs such as psilocybin could be used as efficient treatments for mood disorders such as anxiety and depression.
Beyond the psychological benefits, understanding their physiological acting mechanisms, including the positive effects on neuroinflammatory and neuroplasticity, has greatly inspired a new wave of research. Scientists are now investigating the potential of psychedelic therapies, including magic mushroom, on treating not only mood disorders but also neurodegenerative conditions.
Will psychedelics usher in an era more hopeful for patients suffering from these conditions?
In the U.S., one of the pioneering institutions in this new research of the medicinal potential of psychedelic therapies is Johns Hopkins University. According to trusted providers of premier psilocybe cubensis spores, the Center for Psychedelic and Consciousness Research initiated a study to investigate whether psychedelic-assisted therapy could actually have a positive impact in people with Alzheimer’s who also suffer from depression (these two conditions frequently occur together and it is estimated that depression affects almost 40% of patients with Alzheimer’s).
However, knowing the positive effects of psychedelics on neuroplasticity and neuroinflammation, could they help more than just in depression?
There are a few synthetic psychedelic molecules that could serve as an interesting object of research. Some with stronger anti-inflammatory properties than those of LSD have already been identified. Others have been able to isolate the location of anti-inflammatory activity and generate psychedelic-like molecules, which lose their consciousness-altering properties while preserving their physiological benefits.